The Celiac Serologic Panel: Getting It Right the First Time

 

The Celiac Serologic Panel: Getting It Right the First Time

Two tests, one massive pitfall, and the number-one mistake that makes the whole workup useless.

Celiac disease affects roughly 1 in 100 people, but up to 80% of cases remain undiagnosed. It masquerades as IBS, iron deficiency anemia, unexplained osteoporosis, chronic fatigue, infertility, and even "normal" GI symptoms that patients have lived with for years. The serologic panel is straightforward—but there are pitfalls that will make you miss the diagnosis entirely if you don't know them.

Let's get this one right.

The Tests: What to Order and Why

The First-Line Screen: tTG-IgA + Total IgA

That's it. For most patients over age 2, you need exactly two tests:

1

tTG-IgA (Tissue Transglutaminase IgA Antibody)
The preferred screening test per ACG, AGA, and ESPGHAN guidelines. Sensitivity of 93–98%, specificity of 96–98%. This is the workhorse of celiac diagnosis. If it's positive, you're on the right track. If it's strongly positive (>10× upper limit of normal), that alone may be sufficient for diagnosis in children without biopsy (per ESPGHAN criteria).

2

Total Serum IgA
This is the test that gets forgotten—and it's the one that saves you from a false negative. Selective IgA deficiency occurs in 2–3% of celiac patients (compared to 1 in 400–800 in the general population). If your patient is IgA-deficient, every IgA-based celiac test will be falsely negative. You need this result to know whether you can trust the tTG-IgA.

The #1 Mistake

Ordering tTG-IgA without a total IgA level. If your patient happens to be IgA-deficient, a negative tTG-IgA means nothing. You've just given them a false all-clear for celiac disease. Always order both together.

When IgA Is Deficient: The IgG Backup Panel

If total IgA is low or undetectable, switch to IgG-based tests:

• DGP-IgG (Deamidated Gliadin Peptide IgG) — the preferred IgG test in the setting of IgA deficiency. Slightly better sensitivity than tTG-IgG.
• tTG-IgG — less specific than tTG-IgA; should only be used if IgA deficiency is confirmed. In IgA-sufficient patients, tTG-IgG has an unacceptably high false-positive rate.
• EMA-IgG (Endomysial Antibody IgG) — highly specific but expensive and observer-dependent. Available at some centers.

Key Rule

Never order tTG-IgG in an IgA-sufficient patient. Per AGA best practice advice, IgG isotype testing for tTG is not specific in the absence of IgA deficiency. It will generate false positives and unnecessary endoscopies.

The Other Tests You'll See on Panels

Test	Role	When to Use
tTG-IgA	First-line screening	All patients ≥2 years with suspected celiac disease
Total IgA	Rule out IgA deficiency	Always order alongside tTG-IgA
DGP-IgG	Best IgG alternative	When IgA deficiency is confirmed; also useful in children <2
tTG-IgG	IgG backup	Only in confirmed IgA deficiency (high false-positive rate otherwise)
EMA-IgA	Confirmatory test (~100% specificity)	To confirm a positive tTG-IgA, especially if tTG is >10× ULN (biopsy-free pathway in children)
DGP-IgA	Secondary test	No advantage over tTG-IgA for initial screening; higher false-positive rate
HLA-DQ2/DQ8	Rule-out test (excellent negative predictive value)	If negative, celiac is virtually excluded. Does NOT confirm celiac if positive (30–40% of the general population carries these alleles)

The Pitfalls: Where Clinicians Go Wrong

1. Testing While the Patient Is Already Gluten-Free

This is the single most destructive mistake in celiac testing. If the patient has already eliminated or significantly reduced gluten, both serology and biopsy may be falsely negative. Antibody levels decline within weeks to months on a gluten-free diet (GFD), and villous atrophy can begin healing.

Critical Rule

Do NOT allow the patient to start a GFD before completing the diagnostic workup. If they've already started one, they need a gluten challenge (consuming gluten daily for at least 2–6 weeks, ideally 6–12 weeks) before testing. Many patients are unwilling to do this after they've felt better gluten-free—which is why getting the testing done first is so important.

2. Forgetting Total IgA

Worth repeating: 2–3% of celiac patients are selectively IgA-deficient. Without checking total IgA, you may reassure an IgA-deficient celiac patient that they don't have the disease. This is a preventable miss.

3. Ordering the Full Panel Instead of the Right Tests

Many labs offer "celiac panels" that include tTG-IgA, tTG-IgG, DGP-IgA, DGP-IgG, and sometimes EMA. Per the AAFP Choosing Wisely recommendation, don't order tTG-IgG or DGP antibodies as initial screening tests. They have higher false-positive rates and add cost without improving diagnostic accuracy in IgA-sufficient patients. Start with tTG-IgA + total IgA. Add IgG tests only if IgA deficiency is confirmed.

4. Low-Positive tTG-IgA Results

False-positive tTG-IgA results occur, typically at low titers (1–2× the upper limit of normal). These can be seen in type 1 diabetes, autoimmune thyroid disease, autoimmune liver disease, heart failure, and other inflammatory conditions. A low-positive tTG-IgA should be confirmed with EMA or repeated before committing the patient to endoscopy. Strongly positive results (>10× ULN) are much more reliable.

5. Assuming a Positive Serology = Celiac Disease

In adults, a positive tTG-IgA should lead to referral for endoscopic duodenal biopsy to confirm the diagnosis before starting a GFD. Serology alone is not diagnostic in adults per current ACG guidelines. In children and adolescents, the ESPGHAN guidelines do allow a biopsy-free diagnosis if tTG-IgA is >10× ULN AND EMA-IgA is positive on a second, separate blood draw—but this decision should be made by a pediatric gastroenterologist.

6. Children Under 2: Use DGP Too

In very young children, tTG-IgA may be less sensitive. ACG guidelines recommend adding DGP-IgA and DGP-IgG to the workup in children under 2 years of age. The immune response to gluten takes time to develop, and these children need to have been eating gluten-containing foods for a sufficient period before testing will be accurate.

7. HLA Testing: Great for Ruling OUT, Not for Ruling IN

HLA-DQ2 and HLA-DQ8 are present in virtually all celiac patients. But they're also carried by 30–40% of the general population, most of whom will never develop celiac disease. The value of HLA testing is its negative predictive value: if a patient is DQ2/DQ8-negative, celiac disease is essentially excluded. This is particularly useful for first-degree relatives being considered for lifelong screening, or for patients already on a GFD where serology is unreliable.

Who Should Be Tested?

Test When You See

• Chronic or recurrent diarrhea, bloating, abdominal pain (especially if labeled "IBS")
• Unexplained iron deficiency anemia (especially if refractory to supplementation)
• Unexplained weight loss or failure to thrive in children
• Unexplained osteoporosis or osteopenia, particularly in premenopausal women or men
• Dermatitis herpetiformis (intensely pruritic blistering rash on elbows, knees, buttocks—this IS celiac disease of the skin)
• Recurrent aphthous stomatitis (canker sores)
• Unexplained elevated transaminases
• Peripheral neuropathy without other explanation
• Dental enamel defects
• Unexplained infertility or recurrent miscarriage
• First-degree relatives of celiac patients
• Type 1 diabetes (associated autoimmune condition—screen if symptomatic)
• Autoimmune thyroid disease, Down syndrome, Turner syndrome, Williams syndrome

Do NOT Test

• As population screening in asymptomatic, low-risk individuals
• While the patient is already on a GFD (results will be unreliable)
• With tTG-IgG or DGP as first-line tests in IgA-sufficient patients

The Autoimmune Connection

This is where celiac testing intersects with the rest of this blog series. Celiac disease clusters with other autoimmune conditions:

• Type 1 diabetes — 3–8% of T1D patients have celiac disease
• Hashimoto's thyroiditis and Graves' disease — increased prevalence
• Autoimmune liver disease — celiac can cause cryptogenic transaminitis
• Sjögren's syndrome, SLE, RA — shared autoimmune susceptibility
• Selective IgA deficiency — both associated with celiac AND causes false-negative testing
• Dermatitis herpetiformis — the skin manifestation of celiac disease; always biopsy the uninvolved skin adjacent to the lesion (direct immunofluorescence shows granular IgA deposits at the dermal papillae)

If you're working up one autoimmune condition, keep celiac in the differential—especially if the patient has unexplained anemia, GI symptoms, or weight changes.

Monitoring After Diagnosis

Once celiac disease is confirmed and a GFD is started:

• Recheck tTG-IgA (or DGP-IgG if IgA-deficient) at 3–6 months after diagnosis
• Continue checking every 6 months until levels normalize
• Then annually to monitor GFD adherence
• Persistent or rising antibodies suggest ongoing gluten exposure (intentional or inadvertent)
• Screen for nutritional deficiencies at diagnosis: iron, B12, folate, vitamin D, calcium, zinc
• Repeat DEXA scan if osteopenia/osteoporosis was present at diagnosis

Quick-Reference: The Celiac Testing Algorithm

Scenario	What to Order	Next Step
Standard screen (age ≥2)	tTG-IgA + total IgA	If tTG-IgA positive → refer GI for biopsy
IgA deficient	DGP-IgG (± tTG-IgG)	If positive → refer GI for biopsy
Children <2 years	tTG-IgA + DGP-IgA + DGP-IgG + total IgA	Refer pediatric GI for interpretation
Low-positive tTG-IgA (1–2× ULN)	Confirm with EMA-IgA or repeat tTG-IgA	If confirmed → refer for biopsy. If negative on repeat → likely false positive
Already on GFD	HLA-DQ2/DQ8 (to rule out), or gluten challenge then serology	If HLA negative → celiac excluded. If HLA positive → need gluten challenge for definitive testing
Monitoring on GFD	tTG-IgA (or DGP-IgG if IgA-deficient)	Every 6 months until normal, then annually

Bottom Line

Celiac testing is deceptively simple: two tests will get you there in most cases. But the pitfalls are real—forgetting total IgA, testing on a GFD, ordering the wrong IgG tests in IgA-sufficient patients, and accepting low-positive results without confirmation. Get the order right, make sure the patient is still eating gluten, and always check that total IgA.

For your autoimmune patients especially, celiac disease should live permanently on your differential diagnosis list. It's common, it's underdiagnosed, and it's one of the few autoimmune conditions where the treatment—a gluten-free diet—can fully control the disease.

Stay sharp out there.

The Myositis Antibody Panel: Decoding the Alphabet Soup of Inflammatory Muscle Disease

 

The Myositis Antibody Panel: Decoding the Alphabet Soup of Inflammatory Muscle Disease

When your patient has unexplained elevated CPK and weakness, these antibodies tell you what you're really dealing with—and what's coming next.

Here's a scenario every primary care NP has seen: a patient comes in with fatigue, proximal weakness, and a CPK that's through the roof. The reflexive move is to think statin myopathy, rhabdomyolysis, or maybe hypothyroid myopathy. But what if the CPK stays elevated, the weakness progresses, and the usual suspects are ruled out?

That's when you need to think about idiopathic inflammatory myopathies (IIM)—and the myositis-specific antibody panel becomes your most powerful diagnostic tool.

The Big Picture: What Are Inflammatory Myopathies?

The IIMs are a group of autoimmune diseases that attack skeletal muscle. They include:

• Dermatomyositis (DM) — muscle weakness plus characteristic skin findings (heliotrope rash, Gottron's papules, V-sign, shawl sign)
• Polymyositis (PM) / Antisynthetase Syndrome (AS) — proximal weakness, interstitial lung disease (ILD), arthritis, Raynaud's, mechanic's hands. Note: "polymyositis" as a standalone diagnosis is increasingly rare; most cases reclassify into antisynthetase syndrome, IMNM, or inclusion body myositis with modern testing
• Immune-Mediated Necrotizing Myopathy (IMNM) — severe weakness with very high CPK, necrotizing pathology on biopsy, often associated with statin exposure
• Inclusion Body Myositis (IBM) — typically affects older men, distal and proximal weakness, poor response to immunosuppression. No reliable MSA marker.

Each subtype has distinct antibody associations, which predict clinical phenotype, organ involvement, cancer risk, and prognosis. This is why the panel matters so much.

Myositis-Specific vs. Myositis-Associated Antibodies

An important distinction first:

• Myositis-Specific Antibodies (MSA) — about 90% specific for IIM. They are generally mutually exclusive (a patient typically has only one). Finding two or more MSAs simultaneously should raise suspicion for a false positive.
• Myositis-Associated Antibodies (MAA) — found in myositis patients but also in other CTDs (SLE, scleroderma, Sjögren's). These include anti-Ro52, anti-U1-RNP, and anti-PM/Scl. Helpful for identifying overlap syndromes but not diagnostic for myositis on their own.

Key Concept

Approximately 50% of patients with IIM will have a detectable MSA. The other 50% are seronegative. A negative myositis panel does NOT rule out myositis. Diagnosis still requires clinical assessment, CPK levels, EMG/MRI, and often muscle biopsy.

The Antibodies: What Each One Tells You

The Antisynthetase Antibodies (Antisynthetase Syndrome)

These target aminoacyl-tRNA synthetase enzymes. The clinical syndrome they define—antisynthetase syndrome—is characterized by myositis, interstitial lung disease (ILD), non-erosive arthritis, Raynaud's phenomenon, mechanic's hands (cracked, fissured skin on the lateral fingers), and fever.

Anti-Jo-1

Target: Histidyl-tRNA Synthetase

The most common MSA overall, found in 15–25% of PM/DM patients. The only MSA included in the 2017 EULAR/ACR IIM classification criteria. Strongly associated with ILD, arthritis, mechanic's hands, and Raynaud's. Generally predicts a better response to steroids than some other MSAs, but ILD can still be severe and progressive.

Anti-PL-7, Anti-PL-12, Anti-EJ, Anti-OJ, Anti-KS, Anti-Zo, Anti-Ha

Target: Other Aminoacyl-tRNA Synthetases

Each is individually rare (1–5% prevalence), but collectively they define the same antisynthetase syndrome spectrum. Anti-PL-7 and anti-PL-12 are the most clinically significant after Jo-1. Anti-PL-12 in particular may present as ILD without significant myositis—don't wait for CPK elevation to suspect it.

Dermatomyositis-Specific Antibodies

Anti-Mi-2

Target: Nucleosome Remodeling Deacetylase Complex

The classic DM antibody. Associated with the "textbook" DM presentation: heliotrope rash, Gottron's papules, proximal weakness. Good prognosis. Typically responds well to standard immunosuppressive therapy. Lower risk of ILD and malignancy compared to other DM antibodies.

Anti-TIF1γ (Anti-p155/140)

Target: Transcription Intermediary Factor 1γ

⚠ CANCER SCREENING REQUIRED. Found in 20–30% of adult DM patients. In adults, this antibody carries a strong association with occult malignancy (up to 40–80% of adult patients in some series). Any adult with positive anti-TIF1γ needs comprehensive cancer screening at diagnosis and ongoing surveillance. In children, this antibody is associated with severe skin disease but NOT cancer.

Anti-NXP-2 (Anti-MJ)

Target: Nuclear Matrix Protein 2

⚠ CANCER SCREENING REQUIRED IN ADULTS. Associated with DM in both children and adults. In children, strongly linked to calcinosis (calcium deposits in soft tissues). In adults, carries an increased risk of malignancy, similar to anti-TIF1γ, though data is still evolving. Also associated with severe myopathy, dysphagia, and subcutaneous edema.

Anti-MDA5 (Anti-CADM-140)

Target: Melanoma Differentiation-Associated Gene 5

⚠ RAPIDLY PROGRESSIVE ILD — THIS IS AN EMERGENCY. Specific for DM, particularly clinically amyopathic DM (skin findings without significant muscle weakness or CPK elevation). The hallmark complication is rapidly progressive interstitial lung disease that can be fatal within weeks to months without aggressive treatment. Also associated with painful skin ulcers, palmar papules, and arthritis. If you see this antibody, the patient needs pulmonology and rheumatology urgently.

Anti-SAE

Target: Small Ubiquitin-Like Modifier Activating Enzyme

Rare. Associated with DM that often begins with skin manifestations and progresses to muscle involvement over time. In adults, also carries an increased cancer risk. Dysphagia is common.

Necrotizing Myopathy Antibodies

Anti-SRP

Target: Signal Recognition Particle

Associated with immune-mediated necrotizing myopathy (IMNM). Severe, acute-onset proximal weakness with very high CPK (often >10,000). Biopsy shows necrosis with minimal inflammation. Often treatment-resistant—may require aggressive immunosuppression (IVIG, rituximab). Can have cardiac involvement. In children, may mimic muscular dystrophy with slowly progressive weakness.

Anti-HMGCR

Target: HMG-CoA Reductase

The statin-associated myopathy antibody—but it can also occur in statin-naïve patients. Causes IMNM with very high CPK. This is NOT regular statin myalgia. Stopping the statin alone is insufficient; these patients require immunosuppressive therapy. Important: anti-HMGCR is NOT included in most standard myositis panels and must be ordered separately.

The Master Reference Table

Antibody	Disease	Key Clinical Features	Red Flag
Anti-Jo-1	Antisynthetase syndrome	Myositis, ILD, arthritis, mechanic's hands, Raynaud's	ILD can be severe and progressive
Anti-PL-7/PL-12	Antisynthetase syndrome	ILD-predominant; PL-12 may present as ILD without myositis	Don't wait for elevated CPK
Anti-Mi-2	Dermatomyositis	Classic DM rash + weakness; good steroid response	Best prognosis of the DM antibodies
Anti-TIF1γ	Dermatomyositis	Skin-predominant DM in adults	Cancer screening mandatory in adults
Anti-NXP-2	Dermatomyositis	Calcinosis (children), severe myopathy, dysphagia	Cancer risk in adults; calcinosis in children
Anti-MDA5	Amyopathic DM	Skin ulcers, palmar papules, minimal muscle involvement	Rapidly progressive ILD — emergency
Anti-SAE	Dermatomyositis	Skin-first DM progressing to myositis, dysphagia	Cancer risk in adults
Anti-SRP	IMNM	Severe acute weakness, very high CPK, cardiac risk	Treatment-resistant; needs aggressive immunosuppression
Anti-HMGCR	IMNM	Statin-associated (or statin-naïve) necrotizing myopathy	Must order separately; stopping statin is not enough

The Pitfalls: What Trips Up Clinicians

1. Elevated Transaminases ≠ Liver Disease

This was covered in the autoimmune serologic testing review too, and it bears repeating. AST is released from both liver and muscle. A patient with inflammatory myopathy may present with elevated AST and ALT and get sent to hepatology. Always check CPK when transaminases are elevated without clear liver disease. If CPK is significantly elevated, you're looking at muscle, not liver.

Don't Miss This

A patient referred for "unexplained elevated transaminases" who also has proximal weakness, rash, or arthritis needs a CPK and a myositis workup—not a liver biopsy.

2. Weak Positives on Immunoblot Panels Are Unreliable

Most commercial myositis panels use line immunoassay (immunoblot), which reports results as negative, weak positive, or strong positive. Recent studies show that weak positives have a high false-positive rate—more than 1 in 10 patients with non-myositis diseases can show a weak positive. Strong positives are much more clinically meaningful. Always correlate with clinical presentation.

3. MSAs Are Mutually Exclusive (Usually)

If your patient's panel comes back positive for two or more MSAs, be skeptical. True dual-positive MSAs are rare. This pattern is more likely to represent assay cross-reactivity or a false positive, especially with immunoblot-based assays. Discuss with rheumatology before acting on it.

4. Anti-HMGCR Must Be Ordered Separately

This is a huge miss in practice. A patient with statin exposure, very high CPK, and progressive weakness who doesn't improve after stopping the statin may have anti-HMGCR IMNM—but the standard myositis panel won't detect it. You have to specifically order anti-HMGCR antibody. If your patient had statin-associated symptoms that didn't resolve, order this test.

5. Seronegative Myositis Is Real

About half of IIM patients are MSA-negative. A negative panel does not exclude the diagnosis. If the clinical picture is strong (progressive proximal weakness, high CPK, characteristic rash, compatible EMG/MRI findings), the patient still needs referral and likely a muscle biopsy.

6. Don't Use the Myositis Panel as a Screening Test

Ordering an extended myositis panel for vague fatigue or mild CPK elevation without clinical features of IIM will generate false positives and unnecessary anxiety. This is a targeted test for patients with a meaningful pretest probability of inflammatory myopathy.

7. Cancer Screening with Specific Antibodies

Anti-TIF1γ, anti-NXP-2, and anti-SAE in adults carry a significant association with occult malignancy. Cancer screening at diagnosis should include age- and sex-appropriate screenings plus CT of chest, abdomen, and pelvis. Some centers add PET-CT. Screening should be repeated at 3–5 years for high-risk antibodies, as cancers can present after the myositis diagnosis.

When Should NPs Order the Myositis Panel?

Order When You See

• Progressive proximal muscle weakness (difficulty rising from chairs, climbing stairs, lifting arms overhead)
• Significantly elevated CPK (especially >5× normal) without clear mechanical or pharmacologic cause
• Characteristic DM skin findings: heliotrope rash (purple eyelid discoloration), Gottron's papules (scaly plaques over knuckles), V-sign, shawl sign
• Mechanic's hands + Raynaud's + arthritis (think antisynthetase)
• Unexplained ILD, especially in a younger patient or with accompanying weakness/rash
• Statin myopathy that doesn't resolve after stopping the statin (order anti-HMGCR separately)
• Dysphagia with proximal weakness

Do NOT Order For

• Mild CPK elevation after exercise or minor trauma
• Fibromyalgia or chronic fatigue without objective weakness
• Statin myalgias with normal or mildly elevated CPK that resolve after stopping the statin
• General screening in an ANA-positive patient without muscle or skin symptoms
• Vague complaints without clinical features supporting IIM

The Diagnostic Workflow for Primary Care

1. Recognize the presentation: progressive proximal weakness, elevated CPK, characteristic skin findings, or unexplained ILD.
2. First-line labs: CPK (with isoenzymes if available), aldolase, comprehensive metabolic panel (watch AST/ALT!), CBC, ESR/CRP, TSH, ANA.
3. If IIM is suspected: order the myositis-specific antibody panel. If statin-associated IMNM is suspected, also order anti-HMGCR separately.
4. Refer to rheumatology with labs in hand. Many patients will also need EMG, MRI of affected muscles, and potentially muscle biopsy for definitive diagnosis.
5. If anti-MDA5 is positive: urgent pulmonology referral for ILD evaluation—this can progress to respiratory failure rapidly.
6. If anti-TIF1γ or anti-NXP-2 is positive in an adult: comprehensive age-appropriate cancer screening at diagnosis.

Bottom Line

The myositis-specific antibody panel isn't just an academic exercise. Each antibody maps to a distinct clinical phenotype, predicts specific organ involvement, and changes management. Anti-MDA5 means you're racing against rapidly progressive ILD. Anti-TIF1γ means you're looking for hidden cancer. Anti-HMGCR means stopping the statin isn't going to be enough. Anti-Mi-2 means the prognosis is probably good.

Know your antibodies. Order the right test at the right time. And always check that CPK when the transaminases are up.

Stay sharp out there.

ANCA Testing Demystified: When to Order, How to Interpret, and When to Leave It Alone

 

ANCA Testing Demystified: When to Order, How to Interpret, and When to Leave It Alone

Vasculitis serologies are powerful—but ordering them for the wrong reasons creates more problems than it solves.

ANCA testing is one of the most misused lab panels in primary care. It gets ordered for vague joint pain, nonspecific rashes, or an elevated ESR—and then a low-positive p-ANCA comes back, everyone panics, and the patient gets a workup they never needed. Meanwhile, the patient with bloody nasal crusting and rising creatinine who actually has vasculitis sometimes gets missed because nobody thought to test.

Let's fix that.

What Is ANCA, and What Are We Actually Testing?

ANCA stands for Anti-Neutrophil Cytoplasmic Antibodies. These are autoantibodies directed against proteins inside neutrophils, and they're the serologic hallmark of a group of rare, serious, small-vessel vasculitides collectively called ANCA-associated vasculitis (AAV).

AAV includes three diseases:

• Granulomatosis with polyangiitis (GPA) — formerly Wegener's. Affects the upper and lower respiratory tract and kidneys. Often presents with chronic sinusitis, nasal crusting/bleeding, pulmonary nodules, and glomerulonephritis.
• Microscopic polyangiitis (MPA) — predominantly affects kidneys and lungs. Often presents as rapidly progressive glomerulonephritis and/or alveolar hemorrhage.
• Eosinophilic granulomatosis with polyangiitis (EGPA) — formerly Churg-Strauss. Late-onset asthma, eosinophilia, and multisystem vasculitis. ANCA-positive in only about 30–40% of cases.

The Two Testing Methods: IIF vs. Antigen-Specific Assays

There are two layers to ANCA testing, and understanding both is key to interpreting results correctly:

Indirect Immunofluorescence (IIF) — The Pattern

The original method. Patient serum is applied to ethanol-fixed neutrophils, and the fluorescence pattern is read under a microscope:

• c-ANCA (cytoplasmic pattern) — diffuse granular staining of the cytoplasm. In the context of vasculitis, this is almost always caused by antibodies against proteinase 3 (PR3).
• p-ANCA (perinuclear pattern) — staining concentrated around the nucleus. In vasculitis, this is usually caused by antibodies against myeloperoxidase (MPO).
• Atypical ANCA — positive IIF but negative for both PR3 and MPO on specific assays. This pattern is common in IBD, autoimmune liver disease, and other non-vasculitic conditions. It is not specific for AAV.

Antigen-Specific Assays (ELISA/CLIA) — The Target

These directly measure antibodies against the two key proteins:

• PR3-ANCA (anti-proteinase 3) — the antibody behind most c-ANCA patterns
• MPO-ANCA (anti-myeloperoxidase) — the antibody behind most p-ANCA patterns

Critical Update

Current international guidelines now recommend that antigen-specific testing (PR3 and MPO) can be used as the primary screening method, without requiring IIF first. Many reference labs now default to this approach. The key point: a positive PR3-ANCA or MPO-ANCA in the right clinical context is sufficient to support an AAV diagnosis. IIF alone, particularly an isolated p-ANCA without a positive MPO, is often clinically meaningless for vasculitis.

PR3-ANCA vs. MPO-ANCA: They're Not the Same Disease

Increasingly, experts advocate classifying patients by ANCA serotype rather than just the traditional disease names. The antibody type predicts behavior better than the clinical label alone:

PR3-ANCA (c-ANCA)

• Strongly associated with GPA
• ENT involvement: bloody nasal crusting, sinusitis, saddle-nose deformity, subglottic stenosis
• Pulmonary: nodules, cavitary lesions, alveolar hemorrhage
• Renal: glomerulonephritis
• Higher relapse rate
• More organs typically involved
• More common in Northern European/White populations
• ~75% of GPA patients are PR3-positive

MPO-ANCA (p-ANCA)

• Strongly associated with MPA
• Renal-dominant: often presents as rapidly progressive GN
• Pulmonary: interstitial lung disease, fibrosis, alveolar hemorrhage
• Less ENT involvement
• Lower relapse rate (but relapses still occur)
• More common in Asian and Southern European populations
• ~70% of MPA patients are MPO-positive
• Also seen in ~40% of EGPA

The Pitfalls: Where Primary Care Gets Into Trouble

1. Ordering ANCA for Nonspecific Symptoms

This is pitfall number one, and it's rampant. ANCA gets ordered for fatigue, myalgias, elevated ESR, nonspecific rash, or vague joint pain—and then a low-positive p-ANCA comes back. This almost never means vasculitis.

Remember: p-ANCA (by IIF) without a positive MPO-ANCA is found in a long list of non-vasculitic conditions:

• Inflammatory bowel disease (Crohn's and UC)
• Autoimmune hepatitis and primary sclerosing cholangitis
• Rheumatoid arthritis
• SLE (15–20% of lupus patients can be ANCA-positive)
• Infections
• Various medications

Rule of Thumb

If you don't have a specific clinical reason to suspect small-vessel vasculitis, don't order ANCA. A low pretest probability + a low-positive ANCA = a false positive that generates anxiety, unnecessary referrals, and potentially harmful biopsies. ANCA testing should be driven by clinical suspicion, not used as a screening tool for nonspecific inflammation.

2. Ignoring the 5–10% Who Are ANCA-Negative

Here's the flip side: approximately 5–10% of patients with biopsy-proven GPA or MPA are ANCA-negative. Up to 70% of EGPA patients are seronegative. A negative ANCA does not rule out vasculitis if the clinical picture is compelling. If you have a patient with rapidly progressive glomerulonephritis, pulmonary-renal syndrome, or destructive upper airway disease, they need a rheumatology or nephrology referral regardless of the ANCA result.

3. Confusing "Atypical p-ANCA" with AAV

An atypical ANCA pattern—positive on IIF but negative for both PR3 and MPO—is not associated with ANCA-associated vasculitis. It's most commonly seen in IBD and autoimmune liver diseases. Ordering the antigen-specific assays (PR3 and MPO) is what distinguishes a clinically meaningful result from noise.

4. Drug-Induced ANCA Vasculitis

Several medications can trigger ANCA production and even clinical vasculitis:

• Propylthiouracil (PTU) — the most well-known offender; can cause MPO-ANCA-positive vasculitis with glomerulonephritis and alveolar hemorrhage
• Hydralazine — another common culprit, especially with long-term use
• Minocycline
• Levamisole-adulterated cocaine — causes dual PR3 + MPO positivity with skin lesions and arthralgias
• Anti-TNF agents (infliximab, etanercept) — rare but reported

Clinical Pearl

Always take a thorough medication and substance use history before attributing ANCA positivity to primary vasculitis. Drug-induced ANCA vasculitis often resolves after stopping the offending agent, though severe cases may still require immunosuppression for induction.

5. Using ANCA to Monitor Disease Activity (It's Complicated)

This is a nuanced area. Rising PR3-ANCA levels have a moderately useful association with relapse in GPA—but it's not reliable enough to change treatment based on serology alone. For MPO-ANCA, the data is even less clear. Current practice: serial ANCA levels can be one piece of the monitoring puzzle, but treatment decisions should be based on clinical disease activity, not solely on rising titers.

6. ANCA Can Be Positive After COVID-19 Vaccination (Rarely)

Case reports have described new-onset AAV following SARS-CoV-2 vaccination, including rare cases of dual PR3/MPO positivity. This is exceedingly rare relative to the hundreds of millions of doses administered, but it's worth noting if you see a patient develop vasculitis symptoms in temporal association with vaccination.

When Should NPs Order ANCA?

Order ANCA (PR3 and MPO) When You See

• Rapidly progressive glomerulonephritis (rising creatinine + active urine sediment with RBCs/casts)
• Pulmonary-renal syndrome (GN + alveolar hemorrhage/hemoptysis)
• Chronic destructive sinusitis with bloody/crusting nasal discharge not responding to standard treatment
• Pulmonary nodules or cavitary lesions without clear infectious etiology
• Unexplained alveolar hemorrhage (hemoptysis + bilateral infiltrates)
• Palpable purpura or cutaneous vasculitis
• Mononeuritis multiplex (asymmetric peripheral nerve deficits)
• New-onset severe asthma + eosinophilia + multisystem symptoms (think EGPA)
• Scleritis or orbital pseudotumor
• Subglottic stenosis (especially in a younger patient)

Do NOT Order ANCA For

• Nonspecific fatigue or myalgias
• Isolated elevated ESR or CRP without organ-specific findings
• Generalized arthralgias without evidence of vasculitis
• Routine ANA workup add-on (ANCA and ANA are completely different pathways)
• Nonspecific rashes or urticaria
• "Just to be thorough" — this is how false positives are born

Quick-Reference Table

Pattern/Antibody	Primary Association	Key Pitfall
c-ANCA / PR3-ANCA	GPA (Wegener's); ~90% concordance between c-ANCA and PR3	Higher relapse rate; rising titers may precede flare but aren't reliable enough alone to change therapy
p-ANCA / MPO-ANCA	MPA, EGPA, drug-induced vasculitis	p-ANCA pattern on IIF WITHOUT positive MPO is usually IBD, autoimmune liver disease, or other non-vasculitic cause
Atypical ANCA	IBD (especially UC), autoimmune hepatitis, PSC	NOT associated with AAV. Don't refer for vasculitis workup based on this alone.
ANCA-negative AAV	5–10% of GPA/MPA; up to 70% of EGPA	Negative ANCA does NOT exclude vasculitis. Biopsy may still be needed if clinical suspicion is high.
Drug-induced ANCA	PTU, hydralazine, minocycline, levamisole/cocaine	Usually MPO-ANCA positive; often resolves after stopping the offending drug. Always take a med/substance history.

The Diagnostic Workflow for Primary Care

1. Clinical suspicion first. Don't order ANCA without organ-specific signs pointing toward small-vessel vasculitis.
2. Order PR3-ANCA and MPO-ANCA (antigen-specific assays). Some labs will reflex to IIF if positive; others run all three simultaneously.
3. Get a urinalysis with microscopy at the same time. Active sediment (dysmorphic RBCs, RBC casts, proteinuria) in the setting of positive ANCA is an emergency.
4. Check CRP, ESR, CBC, BMP (creatinine!), and a chest X-ray if pulmonary symptoms are present.
5. Refer urgently. AAV can be life-threatening. If you have a positive PR3 or MPO with compatible clinical findings, this is a same-week (or same-day) referral to rheumatology or nephrology. Do not wait for the specialist appointment to recheck labs.
6. If ANCA is positive but the clinical picture doesn't fit (no organ involvement, no active sediment, no pulmonary findings), don't panic. Consider the pretest probability and alternative explanations (medications, IBD, other autoimmune disease). Refer for evaluation but communicate clearly that the clinical question is "is this a real positive?"

Bottom Line

ANCA testing is powerful but only when it's ordered for the right reasons. The diseases it helps diagnose—GPA, MPA, EGPA—are rare, aggressive, and treatable, but they require a high index of suspicion and a disciplined approach to testing. A positive ANCA in the right clinical context can be lifesaving. A positive ANCA in the wrong context is just noise that generates expensive, anxiety-provoking workups for conditions the patient doesn't have.

Know when to order it. Know what the patterns mean. And know when to leave it alone.

Stay sharp out there.